← Back to Search

Caffeine Consumption for Glaucoma

N/A

Recruiting

Led By M. Reza Razeghinejad, MD

Research Sponsored by Wills Eye

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age 18 to 90 years

Diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)

Must not have

Diseases, ophthalmic or systemic, that are likely to affect OCTA results

Greater than moderate cataract

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, hour 1, hour 2

Awards & highlights

Summary

This trial studied the effects of caffeine on blood flow in the eyes of healthy young adults.

Who is the study for?

This trial is for adults aged 18-90 with primary open-angle glaucoma, as well as healthy individuals without eye diseases. It's not suitable for those with conditions affecting eye test results, severe cataracts, nystagmus, macular degeneration (except mild), diabetic retinopathy, certain optic neuropathies or corneal issues, rheumatologic diseases like Raynaud's phenomenon, pregnant or breastfeeding women, mental illness or alcohol addiction.

What is being tested?

The study is looking at the effects of a caffeine tablet on people with glaucoma compared to healthy subjects. The focus is on how caffeine influences ocular blood flow and potentially affects the vascular system within the eyes.

What are the potential side effects?

Caffeine may cause side effects such as jitteriness, increased heart rate, trouble sleeping (insomnia), upset stomach and restlessness. People who are sensitive to caffeine might also experience headaches and dizziness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 90 years old.

Select...

I have been diagnosed with primary open angle glaucoma.

Select...

I have healthy eyes with no eye diseases.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have no eye or systemic diseases affecting OCTA results.

Select...

I have a severe cataract.

Select...

I experience involuntary eye movements.

Select...

I have a specific type of glaucoma or nerve damage in my eye not caused by glaucoma.

Select...

I have swelling in my retina, had laser treatment on my retina, or have inflammation in my retina or choroid.

Select...

I have a rheumatic disease or Raynaud's phenomenon.

Select...

I have bladder symptoms, heart issues, or sleep problems.

Select...

I have diabetic retinopathy.

Select...

My macular degeneration is more severe than just having mild drusen or pigment changes.

Select...

I have a condition affecting the shape and clarity of my cornea.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, hour 1, hour 2

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, hour 1, hour 2

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, hour 1, hour 2 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Eye

Trial Design

2Treatment groups

Active Control

Group I: Glaucoma PatientsActive Control1 Intervention

Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.

Group II: Healthy controlsActive Control1 Intervention

Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.

0 / 13Eligibility criteria met

Find a Location

Who is running the clinical trial?

Wills EyeLead Sponsor

80 Previous Clinical Trials

15,356 Total Patients Enrolled

49 Trials studying Glaucoma

9,916 Patients Enrolled for Glaucoma

M. Reza Razeghinejad, MD5.07 ReviewsPrincipal Investigator - Wills Eye Hospital

Wills Eye

1 Previous Clinical Trials

50 Total Patients Enrolled

1 Trials studying Glaucoma

50 Patients Enrolled for Glaucoma

5Patient Review

This medical professional was very competent and knew exactly what they were doing.

Media Library

Glaucoma Patients Clinical Trial Eligibility Overview. Trial Name: NCT03675412 — N/A

Glaucoma Research Study Groups: Glaucoma Patients, Healthy controls

Glaucoma Clinical Trial 2023: Glaucoma Patients Highlights & Side Effects. Trial Name: NCT03675412 — N/A

Glaucoma Patients 2023 Treatment Timeline for Medical Study. Trial Name: NCT03675412 — N/A

~14 spots leftby Dec 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.